Bone cancer

Breast Cancer

General Oncology

Gynecological Cancers

Head and neck cancer

Lung Cancer

Radiation Oncology

Carboplatin versus cisplatin: an observational study in locally advanced cervical cancera


Natalia Valdiviezo1 , Iris Otoya1 , Laura Chávez J.1 , Rossana E. Ruiz1 , Norma HuarcayaChombo2 , Yomali Ferreyra3 , Katia Roque1,4, Ofelia Coanqui1 , Mivael Olivera1 , Carlos Velarde Navarrete1,5, Luis Mas López1

Instituto Nacional de Enfermedades Neoplásicas, Av. Angamos Este 2520. Surquillo, Lima, Peru

Correspondence to Author: Iris Otoya Fernández


Background : Cisplatin-based chemoradiation is the standard treatment for locally advanced cervical cancer. However, the toxicity and prolonged infusion time associated with cisplatin urges the search for options that yield similar outcomes. Our objective is to compare the effectiveness of carboplatin versus cisplatin. Methods : The current study is observational and retrospective, consisting of 183 patients with locally advanced cervical cancer who underwent chemoradiation treatment at the National Institute of Neoplastic Diseases, Lima, Peru, between 2014 and 2015. We analyzed their adverse events, response to therapy, disease evolution, and survival outcomes. Results : The squamous cell carcinoma subtype represented 89.6% of the sample, and the most frequent stages were IIB (64%) and IIIC (27%). The trend for complete responses was higher for cisplatin (82%) than carboplatin (77%) but not statistically significant (p=0.3). Neutropenia, diarrhea, and vomiting were the most reported events, with the former being significantly lower in the carboplatin group (p=0.001). At a 5-year follow-up, there was a 41% reduction in the risk of progression and a 28% reduction in risk of death in favor of cisplatin treatment (PFS: HR 0.59, 95% CI 0.34-1.00, p=0.055 and OS: HR 0.72, 95% CI 0.33-1.57, p=0.4). Generally, it was observed that those who achieved a complete response had better survival (p<0.001).

Conclusions : In summary, while there are no differences in efficacy, carboplatin is slightly better tolerated. This suggests that carboplatin could be a valid alternative for patients with a more delicate clinical condition who might face challenges with cisplatin-associated toxicity


Iris Otoya Fernández. Carboplatin versus cisplatin: an observational study in locally advanced cervical cancer. World Journal of Medical Oncology 2024.

Journal Info

  • Journal Name: World Journal of Medical Oncology
  • Impact Factor: 2.709**
  • ISSN: 2766-6077
  • DOI: 10.52338/wjoncgy
  • Short Name: WJMOY
  • Acceptance rate: 55%
  • Volume: 6 (2024)
  • Submission to acceptance: 25 days
  • Acceptance to publication: 10 days


  • Crossref indexed journal impact factor of 2.980**
  • Publons indexed journal impact factor of 3.90**
  • Pubmed-indexed journal impact factor of 5.2**
  • International Scientific Indexing (ISI)-indexed journal impact factor of 2.980**
  • Eurasian Scientific Journal Index (ESJI) index journal impact factor of 2.980**
  • Semantic Scholar indexed journal impact factor of 2.980**
  • Cosmos indexed journal impact factor of 3.981**


  • International Reach
  • Peer Review
  • Rapid Publication
  • Open Access
  • High Visibility